Publications by authors named "S Schiza"
Factors underlying excessive daytime sleepiness (EDS) in obstructive sleep apnea (OSA) are not fully understood. We investigated whether polysomnography (PSG) parameters differed between non-sleepy and sleepy (based on the Epworth Sleepiness Scale (ESS)) OSA patients with the same disease severity, which may play a role in the presence of EDS. A total of 1307 patients, without cardiovascular, metabolic, respiratory, or inflammatory comorbidities, diagnosed with OSA (apnea-hypopnea index (AHI) ≥ 5 per hour of sleep) with type 1 PSG were included.
View Article and Find Full Text PDFStudy Objectives: To assess the impact of the non-respiratory arousal burden at baseline polysomnography (PSG) on residual daytime sleepiness in positive airway pressure (PAP)-treated obstructive sleep apnea (OSA).
Methods: We included OSA patients from the European Sleep Apnea Database registry with available arousal data who had at least 2 treatment follow-up visits. The primary outcome was the Epworth Sleepiness Scale (ESS) score under PAP.
There are controversies regarding the effect of obstructive sleep apnea (OSA) treatment with positive airway pressure (PAP) on diabetes-related outcomes. Therefore, we aimed to explore the association of PAP adherence with diabetes-related outcomes in patients with type 2 diabetes mellitus (T2DM) and OSA. In this prospective study, we included T2DM patients diagnosed with OSA during an 8-year period (2015-2023).
View Article and Find Full Text PDFArticle Synopsis
- Obstructive sleep apnea (OSA) often occurs alongside idiopathic pulmonary fibrosis (IPF), and specific biomarkers like KL-6, ET-1, and S100A9 may help in diagnosing and understanding the severity of these conditions.
- A study involving 55 participants, including those with IPF and IPF-OSA, measured these biomarker levels and examined their relationship with various health factors.
- Although no significant differences in biomarker levels were found between groups, there were trends suggesting higher ET-1 in IPF-OSA, and significant correlations between KL-6 levels and IPF severity, indicating potential for these biomarkers in identifying OSA impact in IPF patients.